Clinical Impact of Liquid Biopsy in Prostatic Cancer: A Literature Review




The most prev amost prev abstract alent solid tumor in men worldwide is prostate cancer. The need for biomarkers to guide management choices is critical given the frequency of prostate cancer and its relatively lengthy clinical course. Based on a patient's unique risk stratification, which considers pathologic characteristics from a prostate biopsy, prostate-specific antigen (PSA) level, imaging, and other patient factors, decisions about localized prostate cancer treatment options, such as active surveillance, surgical excision, or targeted radiation, are made. An attractive method for thorough cancer analysis is to use "liquid biopsies" made up of analytes from a peripheral blood draw. These methods can be used as prognostic and predictive biomarkers as well as ready tissue sources for molecular profiling during the course of a disease and are straightforward, safe, and simple to repeat. Researchers conduct an examination of articles that are in accordance with the issue to be studied. Articles used in literature review are obtained through  the  database  of  international  journal  providers  through  PubMed,  we  investigated eleven clinical studies and discussed what happened in these clinical studies and the extent of the effectiveness of liquid biopsy in  prostatic cancer, in one study there was relative impact of common circulating tumor DNA alterations on patient response to the most widely used large, randomize advanced prostate cancer. Other studies reported that ZNF660 methylation analysis can potentially help to stratify low-/intermediate-grade PCs into indolent vs. more aggressive subtypes. Another study found that tumor-derived biomarkers in platelets of CRPC patients enabled prediction of the outcome after abiraterone therapy with higher accuracy than baseline serum PSA or PSA response. One study reported that de novo positive CTC count after androgen deprivation therapy is probably due to a passive mechanism associated with the destruction of the tumor. In this review, we suggest that liquid biopsy could be used as biomarker for prostatic cancer, Further studies are needed to enhance liquid biopsy efficacy.


Download data is not yet available.


Martins et al., “Liquid biopsies: Applications for cancer diagnosis and monitoring,” Genes (Basel), vol. 12, no. 3, p. 349, 2021.

S. N. Lone et al., “Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments,” Mol. Cancer, vol. 21, no. 1, p. 79, 2022.

M. Sekhoacha, K. Riet, P. Motloung, L. Gumenku, A. Adegoke, and S. Mashele, “Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches,” Molecules, vol. 27, no. 17, p. 5730, 2022.

M. M. Shen and C. Abate-Shen, “Molecular genetics of prostate cancer: new prospects for old challenges,” Genes Dev., vol. 24, no. 18, pp. 1967–2000, 2010.

R. J. Rebello et al., “Prostate cancer,” Nat. Rev. Dis. Primers, vol. 7, no. 1, p. 9, 2021

M. Annala et al., “Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer,” Cancer Discov., vol. 8, no. 4, pp. 444–457, 2018.

C. Haldrup et al., “Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies,” Mol. Oncol., vol. 12, no. 4, pp. 545–560, 2018.

S. Chadid et al., “Association of serum carotenoids and retinoids with intraprostatic inflammation in men without prostate cancer or clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial,” Nutr. Cancer, vol. 74, no. 1, pp. 141–148, 2022.

C. H. Chau et al., “Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial,” PLoS One, vol. 10, no. 5, p. e0126672, 2015.

E. Efstathiou et al., “Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer,” Eur. Urol., vol. 67, no. 1, pp. 53–60, 2015.

L.-A. Tjon-Kon-Fat et al., “Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients,” Prostate, vol. 78, no. 1, pp. 48–53, 2018.

S. K. Steffensen et al., “Benzoxazinoids in prostate cancer patients after a rye-intensive diet: Methods and initial results,” J. Agric. Food Chem., vol. 64, no. 43, pp. 8235–8245, 2016.

A. Zapatero et al., “Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study,” Radiat. Oncol., vol. 15, no. 1, p. 137, 2020.

B. De Laere et al., “TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer,” Clin. Cancer Res., vol. 25, no. 6, pp. 1766–1773, 2019.

E. Cho et al., “External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens,” Int. J. Radiat. Oncol. Biol. Phys., vol. 92, no. 2, pp. 236–243, 2015.

M. Á. Climent et al., “Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial,” Eur. J. Cancer, vol. 87, pp. 30–37, 2017.




How to Cite

M. . Hussein and H. . Ismail, “Clinical Impact of Liquid Biopsy in Prostatic Cancer: A Literature Review”, International Journal of Advanced Health Science and Technology, vol. 3, no. 1, Feb. 2023.



Review Papers